Rabbani, S.A.; El-Tanani, M.; Kumar, R.; Saini, M.; El-Tanani, Y.; Sharma, S.; Aljabali, A.A.A.; Hajeer, E.; Rizzo, M.
Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs. Pharmaceuticals 2025, 18, 1130.
https://doi.org/10.3390/ph18081130
AMA Style
Rabbani SA, El-Tanani M, Kumar R, Saini M, El-Tanani Y, Sharma S, Aljabali AAA, Hajeer E, Rizzo M.
Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs. Pharmaceuticals. 2025; 18(8):1130.
https://doi.org/10.3390/ph18081130
Chicago/Turabian Style
Rabbani, Syed Arman, Mohamed El-Tanani, Rakesh Kumar, Manita Saini, Yahia El-Tanani, Shrestha Sharma, Alaa A. A. Aljabali, Eman Hajeer, and Manfredi Rizzo.
2025. "Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs" Pharmaceuticals 18, no. 8: 1130.
https://doi.org/10.3390/ph18081130
APA Style
Rabbani, S. A., El-Tanani, M., Kumar, R., Saini, M., El-Tanani, Y., Sharma, S., Aljabali, A. A. A., Hajeer, E., & Rizzo, M.
(2025). Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs. Pharmaceuticals, 18(8), 1130.
https://doi.org/10.3390/ph18081130
